BioNovelus' primary target market is the $100Billion* plus, annual, worldwide, coffee industry. (*Source: Business Insider)Forward-Looking Statements This news release includes forward-looking statements covered by the Private Securities Litigation Reform Act of 1995. Because such statements deal with future events, they are subject to various risks and uncertainties and actual results for fiscal year 2016 and beyond could differ materially from the Company's current expectations. Forward-looking statements are identified by words such as "anticipates," "projects," "expects," "plans," "intends," "believes," "estimates," "targets," and other similar expressions that indicate trends and future events. There is no assurance of if and when EPA approval will be obtained for CR-10 and various applications. There is no assurance that the coffee rust application will prove commercially viable. There is no assurance that any transaction will be done with Starbucks or any members of ICafé. Factors that could cause the Company's results to differ materially from forward looking statements regarding EPA approval and the efficacy of the CR-10 results a delay in EPA approval include the lack of capital needed to complete testing, the lack of experience with pursuing approval of this product and modifications that may be demanded by the EPA of the CR-10 formula. Factors that could cause lower rates of success in CR-10 eradication of fungi in coffee plantations and marijuana fields include the method and timing of applications of CR-10, the impact of heavy rain fall the strength of fungi contamination, and other environmental conditions resulting in re-infection. Factors that may impact transactions with Starbucks and members of ICafé include the alternatives of genetically modified crops, products of competitors, government approvals, and pricing. Factors that could cause the Company's results to differ materially from those expressed in forward-looking statements include, without limitation, variation in demand and acceptance of the Company's products and services, general business and economic conditions beyond the Company's control the consequences of competitive factors in the marketplace including the ability to attract and retain customers, results of continuous improvement and other cost-containment strategies, and the Company's success in attracting and retaining key personnel. The Company undertakes no obligation to revise or update forward-looking statements as a result of new information, since these statements may no longer be accurate or timely.
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, and are subject to Rule 3B-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this press release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.For additional information: http://bionovelus.com ###
Media contact: Nathalie Ekobo, Marketing & Communications Director BioNovelus, Inc. +1 602-888-3424 Info@BioNovelus.com